Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Schizophrenia “non-responders” may need more time, study finds
10+ hour, 44+ min ago (482+ words) A paper, published in Lancet Psychiatry, found that some symptoms can improve within the trial timeframe, but others may take longer to show benefit. A paper, published in Lancet Psychiatry, looked at individual participant data (IPD) from six antipsychotic drug…...
Patient death puts Newron’s late-stage schizophrenia trial on ice
3+ mon, 4+ day ago (384+ words) An independent international safety monitoring board has given the ENIGMA-TRS 1 trial the go-ahead to continue as planned. US regulators have pressed pause on enrolment to Newron Pharmaceuticals’ Phase III trial on lead schizophrenia candidate, evenamide, after a patient death. The…...
Spinogenix’s Fragile X Syndrome drug shows normalisation of brain function
3+ mon, 3+ week ago (476+ words) In the Phase IIa study, 10 adult male patients with FXS received one oral dose of SPG601. Spinogenix’s Fragile X Syndrome (FXS) drug is the first to show rescued well-established resting EEG abnormalities, suggesting a normalisation of brain function. The Phase IIa…...
Ayahuasca-derived DMT study shows positive effects on depression therapy in trials
4+ mon, 5+ day ago (342+ words) Clinical Trials Arena Interest in psychedelic medicines has accelerated in recent years, and new research focusing on dimethyltryptamine (DMT), the main psychoactive compound found in ayahuasca, has been found to have positive results. Early clinical findings suggest the compound may…...
Study explores links between gestational diabetes, prenatal depression and childhood obesity
4+ mon, 3+ week ago (519+ words) In the February 2026 edition of JAMA Network Open, a study explored the impact of two health indicators, gestational diabetes and maternal prenatal depression, on childhood obesity. In the US, the burden of childhood obesity has posed a formidable public health…...
Helus’ DMT psychedelic touts antidepressant potential in Phase IIa study
5+ mon, 2+ week ago (617+ words) These results come as the race to commercialise the first FDA-approved psychedelic continues. Helus Pharma’s psychedelic compound, SPL026, has demonstrated its potential to treat major depressive disorder (MDD) in a mid-stage study. During a Phase IIa trial (NCT04673383), 34 patients with moderate-to-severe MDD…...
Newron randomises first subjects in Phase III programme for schizophrenia
11+ mon, 3+ week ago (335+ words) The results from the 12-week analysis are expected to be disclosed in the fourth quarter of 2026. This announcement was made by the company after it completed a screening period for 42 days and a review of subjects by the Independent Eligibility…...